Your browser doesn't support javascript.
loading
Infectious mononucleosis due to Epstein-Barr virus reactivation in an immunocompromised 60-year-old patient with COVID-19.
Harada, Naonori; Shibano, Ikumi; Izuta, Yuto; Kizawa, Yusuke; Shiragami, Hiroshi; Tsumura, Akiko; Ohji, Goh; Mugitani, Atsuko.
Afiliación
  • Harada N; Department of Hematology, Fuchu Hospital, Osaka, Japan. Electronic address: harada.naonori@omu.ac.jp.
  • Shibano I; Department of Hematology, Fuchu Hospital, Osaka, Japan.
  • Izuta Y; Department of Hematology, Fuchu Hospital, Osaka, Japan.
  • Kizawa Y; Department of Hematology, Fuchu Hospital, Osaka, Japan.
  • Shiragami H; Department of Hematology, Fuchu Hospital, Osaka, Japan.
  • Tsumura A; Department of Infectious Diseases, Fuchu Hospital, Osaka, Japan.
  • Ohji G; Division of Infectious Disease Therapeutics, Department of Infectious Disease, Kobe University Graduate School of Medicine, Japan.
  • Mugitani A; Department of Hematology, Fuchu Hospital, Osaka, Japan.
J Infect Chemother ; 30(11): 1182-1185, 2024 Nov.
Article en En | MEDLINE | ID: mdl-38570136
ABSTRACT
Epstein-Barr virus (EBV) reactivation in COVID-19 patients has been reported, but studies on its clinical significance are lacking. We herein report the occurrence of infectious mononucleosis (IM) due to EBV reactivation in a 60-year-old man with rheumatoid arthritis being treated with methotrexate and tocilizumab. The patient presented with a fever and tested positive for COVID-19. Laboratory findings revealed an increased atypical lymphocyte count, decreased platelet count, and elevated liver enzyme levels. Flow cytometry showed predominant expansion of reactive T cells. EBV reactivation was confirmed using real-time polymerase chain reaction. The patient was treated with remdesivir, and clinical improvement was observed after 10 days of treatment. Follow-up showed a gradual decrease in the EBV-DNA load with no recurrence of atypical lymphocytes. These findings suggest that COVID-19 in immunocompromised patients may lead to unexpected EBV reactivation and IM, even for patients outside the age at which IM is likely to occur.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Activación Viral / Huésped Inmunocomprometido / Herpesvirus Humano 4 / SARS-CoV-2 / COVID-19 / Mononucleosis Infecciosa Límite: Humans / Male / Middle aged Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Activación Viral / Huésped Inmunocomprometido / Herpesvirus Humano 4 / SARS-CoV-2 / COVID-19 / Mononucleosis Infecciosa Límite: Humans / Male / Middle aged Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos